Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

Nucs AI

Nucs AI is a cutting-edge solution revolutionizing the clinical management of prostate cancer.
2024
02-Oct
02-10
San Francisco, California, United States
  • Oncology (Cancer)
  • Pathology & Diagnostics
  • Personalized Medicine Technologies
  • Services (Patient care)
  • Urology and Renal

Innovation

Industry Problem

Cancer patients can respond very differently to the same treatment, while current testing may not reliably identify the therapy most likely to work for each tumor.

R&D Focus

Cutting-edge solution revolutionizing the clinical management of prostate cancer

Innovative Solution

The platform harnesses the power of artificial intelligence to offer unparalleled insights into tumor lesions, empowering both patients and healthcare professionals with advanced analyses and evidence-based decision-making tools. It provides detailed assessments of tumor lesions, enabling healthcare professionals to tailor treatment plans to each individual’s unique needs.

Investment Funding

Last Funding Stage

Seed

Total Funding Amount

3.5M

Last Funding Amount

3.5M

Last Funding Date

16-09-2024

Startup Stage

Seed

People

Founders

About

Nucs AI is a cutting-edge solution revolutionizing the clinical management of prostate cancer. The platform harnesses the power of artificial intelligence to offer unparalleled insights into tumor lesions, empowering both patients and healthcare professionals with advanced analyses and evidence-based decision-making tools. With Nucs AI, patients with prostate cancer can navigate their treatment journey with confidence, knowing they have access to the most comprehensive and personalized information available. It provides detailed assessments of tumor lesions, enabling healthcare professionals to tailor treatment plans to each individual’s unique needs. By combining state-of-the-art AI technology with a commitment to patient care, Nucs AI is leading the way in transforming prostate cancer management.

Something missing or incorrect on this page? Help us enrich this information